drugset / Trial / NCT04915482
TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This prospective, open-label, nonrandomized, multicenter clinical trial aims at comparing the efficacy and safety of combined use of TPO-RAs with low-dose anti-CD20 monoclonal antibody vs. the best available therapy（BAT）in adult immune thrombocytopenia with autoantibodies failed (due to intolerance or resistance) to first-line treatment.
Timeline
- Start
- 2021-06-06
- Primary completion
- 2025-01-31
- Completion
- 2025-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avatrombopag | Small molecule | 20 mg | — |
| Subject | Avatrombopag | Small molecule | 40 mg | — |
| Subject | Eltrombopag | Small molecule | 50 mg | — |
| Subject | Eltrombopag | Small molecule | 75 mg | — |
| Subject | Hetrombopag | Small molecule | 5 mg | — |
| Subject | Hetrombopag | Small molecule | 7.5 mg | — |
| Subject | Ortuzumab | Monoclonal antibody | 1000 mg | — |
| Subject | Rituximab | Monoclonal antibody | 100 mg | — |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | — |